A Decentralized Home-Based Study To Investigate Novel Objective Biomarker Of Gluten-Mediated Symptoms Using A Wearable Biosensor And A Mobile Platform In Celiac Disease Participants With And Without Gluten Challenge (CeDar ROSE Study)
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 12
- 试验地点
- 1
- 主要终点
- The concordance between the novel digital biomarker and the presence of celiac disease-related symptoms
研究概览
简要总结
This is a decentralized study to primarily explore a novel objective digital biomarker (i.e., Gluten Dependency Index) for celiac disease-related responses triggered by gluten exposure using a wearable biosensor. This study also explores a novel objective blood biomarker specific to celiac disease activity and evaluates participant symptoms, lifestyle and an objective comprehensive measurement (e.g., activity, stress and sleep) in celiac disease participants.
Approximately 170 well-controlled celiac disease participants (Cohort A) and 40 celiac disease participants with persistent symptoms (Cohort B) will be monitored for 13 and 8 weeks in the observation period, respectively, in a home-based setting using the wearable biosensor along with a mobile platform including some electronic questionnaires.
The wearable biosensor continuously records biosensor data. These data will be used to develop a new algorithm for Gluten Dependency Index and calculate the Gluten Dependency Index, Activity Value, Stress Value, or Sleep Time. Participants will report celiac disease-related symptoms, diet (including any accidental gluten exposures), exercise, menstruation questionnaires in CDSD and mobile platform questionnaire (MPFQ), which is originally designed by the Sponsor.
All participants both in Cohort A and B are required to maintain gluten-free diet throughout the study. Only participant who are enrolled in Cohort A will be required gluten challenge.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Other
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •[Cohort A and B]
- •History of medically diagnosed celiac disease based on biopsies and positive celiac serology.
- •Be on a GFD for at least 12 months
- •Willing and able to adhere to use and management of the wearable device
- •Willingness to comply with home-based approach and visits by a HN professional [Cohort A only]
- •Experienced at most mild symptoms of celiac disease
- •Willingness to consume food containing up to 6 g of gluten protein per challenge day and up to 18 g of gluten protein in total during the study [Cohort B only]
- •Experienced at least 2 different gluten-related symptoms (e.g., diarrhea, abdominal pain, bloating, nausea, tiredness) or 1 gluten-related symptom occurred twice within the month before screening, and at screening were required to have a qualifying score as moderate or severe on at least one symptom on the CDSD in the 14 days recording period.
- •Positive for any of the 3 serology tests, tissue - transglutaminase-2-IgA [tTG2-IgA] (≥4 U/mL), deamidated gliadin peptide-IgA [DGP-IgA] (≥20 U/mL), or deamidated gliadin peptide-IgG [DGP-IgG] (≥20U/mL)
排除标准
- •[Cohort A and B] Refractory celiac disease [Cohort A] Positive for any of the 3 serology tests
- •Tissue transglutaminase-2 [tTG2-IgA] (≥10 U/mL; normal range: 0-3.99 U/mL) prior to the observation period, but weak positive (4-10 U/mL) can be enrolled in this study.
- •Deamidated gliadin peptide-IgA [DGP-IgA], and deamidated gliadin peptide-IgG [DGP-IgG] prior to the observation period, but weak positive (20-30 U/mL) can be enrolled.
- •History of IgE-mediated reactions to wheat, barley, rye, or other ingredients in the gluten products used in the study
结局指标
主要结局
The concordance between the novel digital biomarker and the presence of celiac disease-related symptoms
时间窗: up to 13 weeks
次要结局
- Safety as assessed by percutaneous oxygen saturation(up to 13 weeks)
- The scores of Celiac Disease-related Quality of Life (CDQOL)(up to 13 weeks)
- Safety as assessed by respiratory rate(up to 13 weeks)
- Safety as assessed by blood chemistry test with measuring chemicals(up to 13 weeks)
- Safety as assessed by systolic and diastolic by blood pressure(up to 13 weeks)
- Safety as assessed by urinalysis test with examining the visual, chemical and microscopic aspects(up to 13 weeks)
- Safety as assessed by hematology test with counting blood cells(up to 13 weeks)
- Adverse events' relationship to gluten exposure(up to 13 weeks)
- Correlations between the comprehensive measurement and the scores of patient reported outcomes(up to 13 weeks)
- The comprehensive measurement(up to 13 weeks)
- The scores of Celiac Disease Symptom Diary (CDSD)(up to 13 weeks)
- The scores of Short Form 36 (SF-36)(up to 13 weeks)
- Adverse events(up to 13 weeks)
- Safety as assessed by body temperature(up to 13 weeks)
- Safety as assessed by pulse rate(up to 13 weeks)
- Safety as assessed by Electrocardiograms (heart rate)(up to 13 weeks)
- 3072 Blood biomarkers profile(up to 13 weeks)
- Safety as assessed by coagulation testing with thrombolytic capacity measurement(up to 13 weeks)
- Safety as assessed by Electrocardiograms (QT interval)(up to 13 weeks)
- The incidence of novel digital biomarker (Cohort B only)(up to 13 weeks)
- Celiac disease serology levels(up to 13 weeks)
- 48 Blood biomarker profile(up to 13 weeks)
- Change from baseline in 3072 blood biomarkers profile (Cohort A only)(up to 13 weeks)
- Change from baseline in 48 blood biomarkers profile (Cohort A only)(up to 13 weeks)